X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (98) 98
phenylthiohydantoin - analogs & derivatives (98) 98
male (93) 93
index medicus (86) 86
prostate cancer (79) 79
animals (51) 51
phenylthiohydantoin - pharmacology (46) 46
prostatic neoplasms, castration-resistant - drug therapy (42) 42
oncology (41) 41
cancer (39) 39
cell line, tumor (39) 39
mice (39) 39
enzalutamide (38) 38
phenylthiohydantoin - therapeutic use (35) 35
metastasis (34) 34
androgens (33) 33
prostate (33) 33
androgen receptor (32) 32
urology & nephrology (32) 32
chemotherapy (29) 29
receptors, androgen - metabolism (29) 29
endocrinology & metabolism (28) 28
castration (25) 25
prostatic neoplasms - drug therapy (25) 25
prostatic neoplasms, castration-resistant - pathology (24) 24
antineoplastic agents - therapeutic use (23) 23
aged (22) 22
middle aged (22) 22
phenylthiohydantoin - administration & dosage (22) 22
progression (22) 22
prostatic neoplasms - pathology (22) 22
increased survival (21) 21
abiraterone (20) 20
receptors, androgen - genetics (20) 20
prostatic neoplasms, castration-resistant - metabolism (19) 19
analysis (18) 18
article (18) 18
drug resistance, neoplasm (18) 18
care and treatment (17) 17
expression (17) 17
therapy (17) 17
amino acid sequence (16) 16
antineoplastic agents - pharmacology (16) 16
prostatic neoplasms - metabolism (16) 16
docetaxel (15) 15
gene expression (15) 15
multidisciplinary sciences (15) 15
tumors (15) 15
xenograft model antitumor assays (15) 15
abiraterone acetate (14) 14
androgen antagonists - pharmacology (14) 14
disease progression (14) 14
phenylthiohydantoin - adverse effects (14) 14
aged, 80 and over (13) 13
antitumor-activity (13) 13
cell proliferation - drug effects (13) 13
signal transduction - drug effects (13) 13
androgen receptor antagonists - pharmacology (12) 12
drug resistance, neoplasm - drug effects (12) 12
mice, nude (12) 12
prostatic neoplasms - genetics (12) 12
resistance (12) 12
urology (12) 12
xenografts (12) 12
apoptosis (11) 11
metastases (11) 11
retrospective studies (11) 11
taxoids - therapeutic use (11) 11
treatment outcome (11) 11
androstenes - therapeutic use (10) 10
apoptosis - drug effects (10) 10
cancer therapies (10) 10
drug resistance (10) 10
gene expression regulation, neoplastic - drug effects (10) 10
inhibition (10) 10
neoplasm metastasis (10) 10
orchiectomy (10) 10
prostate-cancer (10) 10
science (10) 10
antineoplastic agents - administration & dosage (9) 9
cell biology (9) 9
deprivation (9) 9
development and progression (9) 9
drug therapy (9) 9
female (9) 9
mechanisms (9) 9
phenylthiohydantoin (9) 9
prostatic neoplasms, castration-resistant - genetics (9) 9
prostatic neoplasms, castration-resistant - mortality (9) 9
research (9) 9
signal transduction (9) 9
survival (9) 9
transcription (9) 9
urologic and male genital diseases (9) 9
activation (8) 8
antiandrogen (8) 8
cells (8) 8
growth (8) 8
immunotherapy (8) 8
patients (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 08/2016, Volume 7, Issue 33, pp. 52810 - 52817
While programmed cell death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration... 
Immune response | Immunotherapy | Immunology and Microbiology Section | Enzalutamide | Immunity | PD-1 | Prostate cancer | DOCETAXEL | INFILTRATION | CELL BIOLOGY | CELL LUNG-CANCER | prostate cancer | PEMBROLIZUMAB | MELANOMA | immunotherapy | PD-L1 | NIVOLUMAB | enzalutamide | IPILIMUMAB | ANTIGEN | Phenylthiohydantoin - adverse effects | Hypothyroidism - chemically induced | Humans | Middle Aged | Prostatic Neoplasms, Castration-Resistant - immunology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Myositis - chemically induced | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Hypothyroidism - immunology | Myositis - immunology | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Prostatic Neoplasms, Castration-Resistant - prevention & control | Prostate-Specific Antigen - metabolism | Antibodies, Monoclonal, Humanized - adverse effects | Phenylthiohydantoin - immunology | Drug Administration Schedule | Programmed Cell Death 1 Receptor - metabolism | Antineoplastic Combined Chemotherapy Protocols - immunology | Prostatic Neoplasms, Castration-Resistant - metabolism | Remission Induction | Phenylthiohydantoin - analogs & derivatives | Phenylthiohydantoin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Prostate-Specific Antigen - immunology | Antibodies, Monoclonal, Humanized - immunology | Drug Resistance, Neoplasm - drug effects
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2011, Volume 108, Issue 23, pp. 9578 - 9582
Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signaling in patients with... 
Antigens | Androgens | Imaging | Cell lines | Androgen antagonists | Prostate cancer | Positron emission tomography | Heterologous transplantation | Tumors | Vehicles | ANTIBODIES | J591 | THERAPY | PHASE-I TRIAL | MULTIDISCIPLINARY SCIENCES | F-18-FDG | EXTRACELLULAR DOMAIN | ANTITUMOR-ACTIVITY | GASTROINTESTINAL STROMAL TUMORS | UP-REGULATION | CANCER | Prostatic Neoplasms - metabolism | Radiopharmaceuticals - immunology | Humans | Receptors, Androgen - metabolism | Immunoblotting | Male | Transplantation, Heterologous | Copper Radioisotopes - pharmacokinetics | Neoplasms, Experimental - pathology | Glutamate Carboxypeptidase II - metabolism | Prostatic Neoplasms - genetics | Heterocyclic Compounds, 1-Ring - chemistry | Neoplasms, Experimental - genetics | Antigens, Surface - metabolism | Dihydrotestosterone - pharmacology | Prostate-Specific Antigen - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Antibodies, Monoclonal - chemistry | Antibodies, Monoclonal - immunology | Phenylthiohydantoin - pharmacology | Prostate-Specific Antigen - genetics | Glutamate Carboxypeptidase II - immunology | Prostatic Neoplasms - pathology | Radiopharmaceuticals - pharmacokinetics | Antigens, Surface - genetics | Androgen Antagonists - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Signal Transduction - genetics | Positron-Emission Tomography - methods | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Phenylthiohydantoin - analogs & derivatives | Orchiectomy | Animals | Glutamate Carboxypeptidase II - genetics | Receptors, Androgen - genetics | Androgens - pharmacology | Signal Transduction - drug effects | Cell Line, Tumor | Mice | Neoplasms, Experimental - metabolism | Antigens, Surface - immunology | Biological Sciences
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 12/2014, Volume 20, Issue 24, pp. 6367 - 6378
Journal Article
Nature, ISSN 0028-0836, 07/2018, Volume 559, Issue 7714, pp. 363 - 369
Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC).... 
IMMUNITY | ENZALUTAMIDE MDV3100 | TUMOR PROGRESSION | PLAQUE PSORIASIS | MULTIDISCIPLINARY SCIENCES | ABIRATERONE ACETATE | MECHANISMS | SUPPRESSOR-CELLS | CLINICAL ACTIVITY | DOCETAXEL | EXPRESSION | Androgen Receptor Antagonists - therapeutic use | Cell Proliferation | Phenylthiohydantoin - therapeutic use | Humans | Receptors, Androgen - metabolism | Androgens - deficiency | Interleukin-23 - blood | Male | Androgen Receptor Antagonists - pharmacology | Prostatic Neoplasms, Castration-Resistant - pathology | Receptors, Interleukin - metabolism | Interleukin-23 - metabolism | Interleukin-23 - antagonists & inhibitors | Myeloid-Derived Suppressor Cells - cytology | Nuclear Receptor Subfamily 1, Group F, Member 3 - metabolism | Prostatic Neoplasms, Castration-Resistant - therapy | Myeloid-Derived Suppressor Cells - metabolism | Phenylthiohydantoin - pharmacology | Myeloid-Derived Suppressor Cells - immunology | Signal Transduction | Cell Survival | Prostatic Neoplasms, Castration-Resistant - blood | Prostatic Neoplasms, Castration-Resistant - metabolism | Interleukin-23 - immunology | Phenylthiohydantoin - analogs & derivatives | Animals | Mice | Castration | Oncology, Experimental | Research | Suppressor cells | Prostate cancer | Methods | Cancer | Cell proliferation | Therapy | Transcription factors | Interleukin 23 | Inactivation | Cancer therapies | Synergism | Metastases | Dependence | Deprivation | Myeloid cells | Cell survival | Deactivation | Psoriasis | Cytokines | Gene expression | Patients | Blood levels | Androgens | Medical prognosis | Infiltration | Prostate | Tumors
Journal Article
European Urology, ISSN 0302-2838, 2016, Volume 70, Issue 4, pp. 599 - 608
Journal Article
Cancer Science, ISSN 1347-9032, 08/2013, Volume 104, Issue 8, pp. 1027 - 1032
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 398, pp. 62 - 69
Abstract Despite the success of androgen-deprivation therapy (ADT) with the newly developed anti-androgen enzalutamide (Enz, also known as MDV3100) to suppress... 
Hematology, Oncology and Palliative Medicine | Natural Killer cells | ARv7 | Enzalutamide | POPULATION | METASTASIS | MAST-CELLS | SIGNALS | FULL-LENGTH | NK CELLS | REPRESSION | ONCOLOGY | IMMUNOTHERAPY | T-CELLS | ABIRATERONE | Chemotaxis, Leukocyte | Alternative Splicing | Coculture Techniques | Humans | Receptors, Androgen - metabolism | Prostatic Neoplasms, Castration-Resistant - immunology | Tumor Microenvironment | Drug Resistance, Neoplasm | Male | MicroRNAs - metabolism | Prostatic Neoplasms, Castration-Resistant - pathology | Receptors, Androgen - drug effects | Time Factors | Killer Cells, Natural - immunology | Lymphocytes, Tumor-Infiltrating - metabolism | Phenylthiohydantoin - pharmacology | Enhancer of Zeste Homolog 2 Protein - metabolism | Antineoplastic Agents, Hormonal - pharmacology | Neoplasm Invasiveness | Down-Regulation | Androgen Antagonists - pharmacology | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Phenylthiohydantoin - analogs & derivatives | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Phenotype | Animals | Signal Transduction - drug effects | Mice, Nude | Protein Isoforms | Cell Line, Tumor | Cell Proliferation - drug effects | MicroRNAs - genetics | Killer Cells, Natural - metabolism | Lymphocytes, Tumor-Infiltrating - immunology | Medicine, Experimental | Medical research | Killer cells | MicroRNA | Hormones | Prostate cancer | Peptides | Cytotoxicity | Metastasis | Assaying | Adoptive transfer | Folic acid | Incidence | Proteins | Bicarbonate | Pore size | Immunotherapy | Bone marrow | American Type Culture Collection | Inhibition | Chambers | Antigens | Pathogens | Immunoglobulins | Splicing | Media | Nucleic acids | Gene expression | Sun | Survival | Gene silencing | Androgens | Inhibitors | Surveillance | Sodium | Stem cells | Biotechnology | Alternative splicing | Media (culture) | Glands | Antibodies | Lymph nodes | Lymphocytes | Modulation | Clumps | Bones | Inserts | Immune system | Immune response | Incubation | Tumor cells | Agar | 2-Mercaptoethanol | Ribonucleic acid--RNA | Adhesion | Solidification | Antibiotics | Lymphocytes B | MicroRNAs | Lysis | Cells (biology) | Porosity | Differentiation
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 22, pp. 1665 - 1675
Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These... 
GROWTH-FACTOR RECEPTOR | CONTROLLED-TRIAL | ANTIANGIOGENIC THERAPY | ONCOLOGY | RANDOMIZED PHASE-II | BONE METASTASES | C-MET | SIPULEUCEL-T APC8015 | ABIRATERONE ACETATE | TUMOR MICROENVIRONMENT | ANGIOGENESIS INHIBITION | Cancer Vaccines - pharmacology | Humans | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Prostatic Neoplasms - immunology | RANK Ligand - pharmacology | Receptors, Androgen - drug effects | Treatment Failure | Prostatic Neoplasms - drug therapy | Phenylthiohydantoin - pharmacology | Tumor Microenvironment - drug effects | Dasatinib | Antibodies, Monoclonal - pharmacology | Angiogenesis Inhibitors - pharmacology | Clusterin - pharmacology | Pyrimidines - pharmacology | Denosumab | Prostate-Specific Antigen - blood | Orchiectomy | Signal Transduction - drug effects | Anilides - pharmacology | Mice | Receptor Cross-Talk - drug effects | Endothelin-1 - antagonists & inhibitors | Immunotherapy - methods | Taxoids - pharmacology | Ipilimumab | Tissue Extracts - pharmacology | Bone Remodeling - drug effects | Pyrrolidines - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Mice, SCID | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Xenograft Model Antitumor Assays | Cancer Vaccines - immunology | Pyrroles - pharmacology | Animals | RANK Ligand - antagonists & inhibitors | Pyridines - pharmacology | Thiazoles - pharmacology | Immune response | Development and progression | Cellular signal transduction | Research | Drug therapy | Health aspects | Prostate cancer | Risk factors | Review
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2013, Volume 19, Issue 22, pp. 6205 - 6218
Purpose: Enzalutamide, a second-generation androgen antagonist, was approved by the U. S. Food and Drug Administration (FDA) for castration-resistant prostate... 
IMMUNE-RESPONSE | ANTITUMOR RESPONSES | DENDRITIC CELLS | ONCOLOGY | RAT VENTRAL PROSTATE | TRANSGENIC MOUSE | ANTIGEN CASCADE | REARRANGEMENT EXCISION CIRCLES | TWIST EXPRESSION | CASTRATION | T-CELLS | Androgen Receptor Antagonists - therapeutic use | Cell Proliferation | Phenylthiohydantoin - therapeutic use | Vaccination | Epithelial-Mesenchymal Transition - drug effects | Male | Antineoplastic Agents - therapeutic use | Cell Movement - genetics | T-Lymphocytes, Regulatory - immunology | Cancer Vaccines - therapeutic use | Receptors, Androgen - drug effects | Neoplasm Metastasis - drug therapy | RNA Interference | Immunotherapy | Twist-Related Protein 1 - immunology | Mice, Inbred C57BL | Urogenital System - drug effects | Lymphocytes, Tumor-Infiltrating - drug effects | Prostatic Neoplasms, Castration-Resistant - drug therapy | Thymus Gland - drug effects | Adenocarcinoma - drug therapy | Survival | Phenylthiohydantoin - analogs & derivatives | T-Lymphocytes, Regulatory - drug effects | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Twist-Related Protein 1 - genetics | Mice | Prostatic Neoplasms, Castration-Resistant - mortality | RNA, Small Interfering | Adenocarcinoma - mortality | ADT | prostate cancer | cancer vaccine | immunotherapy | combination therapy | immunogenic modulation | enzalutamide
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0158952
Journal Article